Clinical Trials Logo

Retinopathy of Prematurity clinical trials

View clinical trials related to Retinopathy of Prematurity.

Filter by:

NCT ID: NCT00346814 Recruiting - Clinical trials for Retinopathy of Prematurity

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Start date: July 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity

NCT ID: NCT00339001 Recruiting - Clinical trials for Retinopathy of Prematurity

Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

Start date: April 2006
Phase: N/A
Study type: Observational

To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.